Interpace Biosciences, Inc 8-K/A, filed Aug 26, 2026
Interpace Biosciences, Inc. (IDXG)
About this 8-K/A
Interpace Biosciences, Inc filed this 8-K/A on August 26, 2026, reporting on events of August 20, 2026.
Items reported
- Item 5.02: Director or officer change, or executive pay
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Amendment No. 1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported)
(Exact name of Registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission
File Number) |
(IRS Employer Identification No.) |
(Address, including zip code, of Principal Executive Offices)
Registrant’s telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| None | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
EXPLANATORY NOTE
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
adoption of 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan and Replacement of 2019 Plans
The Board of Directors of the Company previously approved, subject to stockholder approval, the adoption of the Company’s 2026 Equity Incentive Plan (the “2026 Incentive Plan”) and 2026 Employee Stock Purchase Plan (the “2026 ESPP”) (together, the “2026 Benefit Plans”). At the Company’s annual meeting of stockholders held on August 20, 2026, the Company’s stockholders approved the adoption of the 2026 Benefit Plans. The 2026 Incentive Plan replaces the Company’s 2019 Equity Incentive Plan (the “2019 Incentive Plan”) and the 2026 ESPP replaces the Company’s 2019 Employee Stock Purchase Plan, as amended (the “2019 ESPP”). As such, no further grants of equity awards will be made under the 2019 Incentive Plan and no further purchases will be allowed under the 2019 ESPP.
A description of the material terms and conditions of the 2026 Benefit Plans was previously reported in the Company’s definitive proxy statement filed with the SEC on July 7, 2026, under the headings “Proposal 3 - Approval of the Company’s 2026 Equity Incentive Plan” and “Proposal 4 - Approval of the Company’s 2026 Employee Stock Purchase Plan 4” and each is incorporated herein by reference. The foregoing is qualified in its entirety by reference to the full text of the 2026 Benefit Plans, forms of which are incorporated herein by reference to Exhibits 10.1 and 10.2.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 10.1 | Form of 2026 Equity Incentive Plan, incorporated by reference to Annex C of the Company’s definitive proxy statement, filed with the SEC on July 7, 2026. | |
| 10.2 | Form of 2026 Employee Stock Purchase Plan, incorporated by reference to Annex D of the Company’s definitive proxy statement, filed with the SEC on July 7, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Interpace Biosciences, Inc. | ||
| By | /s/ Thomas W. Burnell | |
| Name: | Thomas W. Burnell | |
| Title: | President and Chief Executive Officer | |
Date August 26, 2026